Andrew Kuykendall: FDA Approves Rusfertide for Polycythemia Vera
Andrew Kuykendall, Associate Member – Depatment of Malignant Hematology at Moffitt Cancer Center, shared Naveen Pemmaraju‘s post on LinkedIn:
”Such exciting news!
This has been an extremely rewarding process. Thankful to the patients who participated in the studies that led to this approval.
Hearing patients talk about how rusfertide improved their lives provided the energy that got this therapy across the finish line. Happy to have been able to play a role.”
Naveen Pemmaraju, Professor, Department of Leukemia and Executive Director – Cancer Medicine at UT MD Anderson, shared a post on LinkedIn:
”Breaking good news this evening to share! We just found out – Rusfertide (PTG-300) approved. MPNSM Polcythemia Vera
I was proud to co-lead this program from PI standpoint along with Dr Andrew Kuykendall as lead.
I am super proud to see this moment for our patients with PV, and for a brand new class of drug therapies Hepcidin Mimetics to become an option for PV Treatment, and to continue to serve as senior global PI leader for the program.
What a moment for our MPNSM field.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge